Source: Geron Corporation
Date: November 13, 2007
Summary:
In an official company news release, Geron Corporation, a biotechnology company in the field of stem cell research, reported its embryonic stem cell therapy to treat spinal cord injury evaded attack by the immune system:
"Geron Corporation today announced the publication of study results showing that GRNOPC1, the company's human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades direct attack by the human immune system in vitro. Published in the November online issue of the Journal of Neuroimmunology, the results of research conducted by Ross Okamura, Ph.D. and other Geron scientists suggest that unlike whole organ transplants, cellular therapeutics derived from hESCs may provoke only minimal immune reactions and that rejection may be controlled or prevented by short courses of low-dose immunosuppressive drugs. The results also support the position that patient-specific hESC lines are not needed to prevent immune rejection."
